Peter Chin From Genentech: Working Toward Filling An Unmet Need In MS Treatment
After receiving breakthrough therapy designation from the US Food and Drug Administration Ocrelizumab cleared another major hurdle in becoming the first treatment approved for progressive multiple sclerosis but more work remains before any potential approval is finalized.
After receiving breakthrough therapy designation from the US Food and Drug Administration Ocrelizumab cleared another major hurdle in becoming the first treatment approved for progressive multiple sclerosis but more work remains before any potential approval is finalized.
Peter Chin, MD, Principal Medical Director for Genentech discussed what the designation means during the annual ACTRIMS meeting in New Orleans. The announcement from the FDA came just as the conference was set to get underway and was one of the focal points of the event which was looking directly at potential treatments for the condition.
